MedTrace Logo

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

NCT00252876 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2000

Last updated 2008-03-17

No results posted yet for this study

Summary

This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2 diabetes during up to 104 weeks of treatment. The total duration, including treatment and follow-up, is 107 weeks.

Conditions

Interventions

DRUG

tesaglitazar

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Galida Medical Science Director, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Completion
2007-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Czechia
  • Estonia
  • Finland
  • Greece
  • Hong Kong
  • Hungary
  • India
  • Indonesia
  • Israel
  • Italy
  • Latvia
  • Lithuania
  • Malaysia
  • Netherlands
  • Philippines
  • Poland
  • Portugal
  • Russia
  • Serbia and Montenegro
  • Singapore
  • Slovakia
  • South Africa
  • South Korea
  • Switzerland
  • United Kingdom
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252876 on ClinicalTrials.gov